A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2002
12/19/2002	US20020192240 Therapy for injured muscles
12/19/2002	US20020192238 Proceture to use staphylococcal bacteria
12/19/2002	US20020192237 Polypeptides containing polymorphisms of the repeated regions of pertactin in bordetella pertussis, bordetella parapertussis, and bordetella bronchiseptica, their use in diagnostics, and in immunogenic compositions
12/19/2002	US20020192234 Antigen strain in vehicle; inducting immunology response
12/19/2002	US20020192233 Tuberculosis vaccine; genetic engineering
12/19/2002	US20020192232 Methods and compositions for impairing multiplication of HIV-1
12/19/2002	US20020192231 Method of increasing anti-neuGc antibody levels in blood
12/19/2002	US20020192230 Therapeutic formulations using heat shock/stress protein-peptide complexes
12/19/2002	US20020192229 MHC class I associated peptides for prevention and treatment of tuberculosis
12/19/2002	US20020192228 Protein markers for lung cancer and use thereof
12/19/2002	US20020192227 Vaccines against cancer and infectious diseases
12/19/2002	US20020192226 Production of a parvovirus vaccine in plants as viral coat protein fusions
12/19/2002	US20020192225 Methods of identifying bacterial genes that are incompatible with bacterial pathogenicity, and the use of such genes, such as cadA, to reduce pathogenicity in a bacteria or to combat pathogenic bacterial infections
12/19/2002	US20020192224 Hepatitis b vaccine
12/19/2002	US20020192222 Receptor specific transepithelial transport of therapeutics
12/19/2002	US20020192220 Compositions and methods relating to colon specific genes and proteins
12/19/2002	US20020192216 Therapeutic use
12/19/2002	US20020192215 Novel uses of mammalian OX2 protein and related reagents
12/19/2002	US20020192209 Methods and compositions for inhibiting neoplastic cell growth
12/19/2002	US20020192205 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
12/19/2002	US20020192199 Composition and methods for enhanced tumor cell immunity in vivo
12/19/2002	US20020192195 Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
12/19/2002	US20020192193 Antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/19/2002	US20020192192 Antigen presenting cells, a process for preparing the same and their use as cellular vaccines
12/19/2002	US20020192190 Induction of immunological tolerance
12/19/2002	US20020192157 Treatment and diagnosis of macrophage mediated disease
12/19/2002	DE10127712A1 Use of immunoglobulin M for treatment and prevention of systemic lupus erythematosus, administered subcutaneously or intramuscularly
12/19/2002	CA2488850A1 Sustained release n-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating cancer
12/19/2002	CA2450285A1 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
12/19/2002	CA2450113A1 Vanilloid receptor-related nucleic acids and polypeptides
12/19/2002	CA2450027A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449934A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002	CA2449649A1 A g-protein coupled receptor and uses therefor
12/19/2002	CA2449602A1 Ns4 nucleic acids and polypeptides and methods of use for the treatment of body weight disorders
12/19/2002	CA2449593A1 Spray freeze-dried compositions
12/19/2002	CA2449517A1 Tissue-specific endothelial membrane proteins
12/19/2002	CA2449440A1 Structural and cytoskeleton-associated proteins
12/19/2002	CA2447791A1 Methods of culturing animal cells and polypeptide production in animal cells
12/19/2002	CA2447687A1 Substituted 1-benzazepines and derivatives thereof
12/19/2002	CA2445605A1 Treatment or prophylaxis of insulin-producing cell graft rejection
12/18/2002	EP1267167A1 Method for identifying HCV entry factors
12/18/2002	EP1266965A2 Recombinant antibodies for human therapy
12/18/2002	EP1266662A2 Synthetic peptide vaccines for dental caries
12/18/2002	EP1266026A1 Modulation of pleiotrophin signaling by receptor-type protein tyrosine phosphatase beta/zeta
12/18/2002	EP1266023A2 LIPOPOLYSACCHARIDES (LPS) EXTRACTED FROM i ESCHERICHIA COLI /i
12/18/2002	EP1266020A2 Production of foreign polypeptides in plants as viral coat protein fusions
12/18/2002	EP1266014A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
12/18/2002	EP1266008A2 Acute neuronal induced calcium binding protein type 1 ligand
12/18/2002	EP1266003A2 Kcnb: a potassium channel protein
12/18/2002	EP1266002A2 Il-17 receptor like molecules and uses thereof
12/18/2002	EP1265999A2 Human schizophrenia gene
12/18/2002	EP1265996A2 Identification of modulators of the interferon gamma signaling pathway and their use in restenosis treatment
12/18/2002	EP1265989A2 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis
12/18/2002	EP1265928A1 Ultra high affinity neutralizing antibodies
12/18/2002	EP1265920A2 Angiogenesis-associated proteins, and nucleic acids encoding the same
12/18/2002	EP1265917A2 Tlp peptides and dna sequences coding the same
12/18/2002	EP1265916A2 Therapeutic anti-cytomegalovirus compounds
12/18/2002	EP1265915A2 Novel compounds
12/18/2002	EP1265914A2 Wnt-1 related polypeptides, and nucleic acids encoding the same
12/18/2002	EP1265840A2 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
12/18/2002	EP1265635A1 Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
12/18/2002	EP1265633A2 Adjuvant for vaccines
12/18/2002	EP1265632A2 Lipopeptide adjuvants
12/18/2002	EP1265631A1 Method for producing vaccines containing a heat-treated mixture consisting of at least one antigen and of at least one adjuvant
12/18/2002	EP1265630A2 Use of insulin for the treatment of cartilagenous disorders
12/18/2002	EP1265626A1 Method for reducing allergen-induced airway hyperresponsiveness
12/18/2002	EP1265624A1 Mycobacterium ag85 complex-specific t cell peptides and use in diagnostic and therapeutic applications thereof
12/18/2002	EP1265622A2 Treatment of herpes infection using immunomodulatory polynucleotide sequences
12/18/2002	EP1265598A1 Pharmaceutical composition for application to mucosal surfaces
12/18/2002	EP0930887B1 Cancer immunotherapy using tumor cells combined with mixed lymphocytes
12/18/2002	EP0925503B1 Materials and methods relating to the diagnosis and treatment of diabetes and obesity
12/18/2002	EP0866803B1 Transferrin receptor protein of moraxella
12/18/2002	EP0784485B1 VACCINE COMPOSITIONS containing partially deacetylated chitin
12/18/2002	EP0769018B1 Helicobacter proteins and vaccines
12/18/2002	EP0715523B1 Purine nucleoside phosphorylase gene therapy for human malignancy
12/18/2002	EP0662150B1 Maspin, a novel serpin with tumor suppressing activity
12/18/2002	EP0646019B9 Biotin-DOTA conjugates and their use in pretargeting methods
12/18/2002	EP0641385B1 Development of dna probes and immunological reagents of human tumor associated antigens
12/18/2002	EP0630255B1 Mhc conjugates useful in ameliorating autoimmunity
12/18/2002	EP0551440B1 Design of bioactive peptides based on immunoglobulin structure
12/18/2002	EP0521996B1 Catalytic antibody components
12/18/2002	CN1385532A Expression system utilizing self-schizolysis fusing protein and novel reduction polypeptide
12/18/2002	CN1385531A Dilutus culex chymotrypsin gene
12/18/2002	CN1385529A Expression system utilizing self-schizolysis fusing protein and novel reduction polypeptide
12/18/2002	CN1385528A Live vaccine for treating anaphylaxis
12/17/2002	US6495661 Isolated nucleic acid molecule encoding the outer membrane protein of pasteurella multocida is provided. also provided are methods to detect the presence of the nucleic acid molecule, and antibodies specific for the polypeptide encoded
12/17/2002	US6495567 Triaryl methane compounds and their use in the treatment of diarrhea and scours
12/17/2002	US6495520 Apoptosis Inducing Molecule II and methods of use
12/17/2002	US6495519 Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
12/17/2002	US6495518 Method for importing biologically active molecules into cells
12/17/2002	US6495361 Method of producing infectious papillomavirus in placental cells
12/17/2002	US6495359 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
12/17/2002	US6495349 Chimeric gene constructs
12/17/2002	US6495346 Do not react with foreign partners; amino acids inserted into proteins which naturally form dimers, mutated proteins only form complexes with themselves (homodimers) or with the mutated partner (heterodimers), not with nonmutated starting
12/17/2002	US6495345 Surface antigen
12/17/2002	US6495332 Methods and compositions for ameliorating the symptoms of sepsis
12/17/2002	US6495330 Determining the level of p-type inositol phosphoglycans in a biological sample obtained from the patient, wherein said p-type ipgs are capable of activating pyruvate dehydrogenase phosphatase, by immunoassay
12/17/2002	US6495321 Randomisation of the entire gene sequence in combination with the selection of a variant (mutant) protein with the desired characteristics, followed by a new round of random mutagenesis and selection
12/17/2002	US6495315 Channel forming toxins as antiviral agents
12/17/2002	US6495146 Administering eimeria spores, oocysts and/or mixtures during incubation of poultry eggs; immunology

1 ... 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 ... 1823